Novartis AG Debt to Equity Ratio 2012-2026 | NVS
Current and historical debt to equity ratio values for Novartis AG (NVS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Novartis AG debt/equity for the three months ending March 31, 2026 was 0.60.
| Novartis AG Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $79.61B | $38.93B | 2.05 |
| 2025-12-31 | $64.40B | $46.55B | 1.38 |
| 2025-09-30 | $62.54B | $44.75B | 1.40 |
| 2025-06-30 | $62.34B | $42.05B | 1.48 |
| 2025-03-31 | $61.49B | $38.45B | 1.60 |
| 2024-12-31 | $58.12B | $44.13B | 1.32 |
| 2024-09-30 | $60.08B | $43.44B | 1.38 |
| 2024-06-30 | $55.60B | $41.90B | 1.33 |
| 2024-03-31 | $54.58B | $39.76B | 1.37 |
| 2023-12-31 | $53.20B | $46.75B | 1.14 |
| 2023-09-30 | $74.45B | $38.25B | 1.95 |
| 2023-06-30 | $59.05B | $51.93B | 1.14 |
| 2023-03-31 | $60.10B | $52.14B | 1.15 |
| 2022-12-31 | $58.03B | $59.42B | 0.98 |
| 2022-09-30 | $57.57B | $60.90B | 0.95 |
| 2022-06-30 | $59.90B | $63.01B | 0.95 |
| 2022-03-31 | $63.51B | $61.70B | 1.03 |
| 2021-12-31 | $63.97B | $67.82B | 0.94 |
| 2021-09-30 | $64.27B | $56.94B | 1.13 |
| 2021-06-30 | $69.89B | $54.13B | 1.29 |
| 2021-03-31 | $71.16B | $50.59B | 1.41 |
| 2020-12-31 | $71.11B | $56.67B | 1.26 |
| 2020-09-30 | $75.12B | $54.55B | 1.38 |
| 2020-06-30 | $69.88B | $53.89B | 1.30 |
| 2020-03-31 | $72.12B | $50.98B | 1.42 |
| 2019-12-31 | $62.82B | $55.55B | 1.13 |
| 2019-09-30 | $63.37B | $52.60B | 1.21 |
| 2019-06-30 | $64.79B | $51.50B | 1.26 |
| 2019-03-31 | $90.64B | $47.31B | 1.92 |
| 2018-12-31 | $66.87B | $78.69B | 0.85 |
| 2018-09-30 | $64.98B | $78.02B | 0.83 |
| 2018-06-30 | $65.16B | $76.90B | 0.85 |
| 2018-03-31 | $64.31B | $71.21B | 0.90 |
| 2017-12-31 | $58.85B | $74.23B | 0.79 |
| 2017-09-30 | $62.60B | $72.37B | 0.87 |
| 2017-06-30 | $63.77B | $69.98B | 0.91 |
| 2017-03-31 | $64.34B | $67.65B | 0.95 |
| 2016-12-31 | $0.00B | 0.00 | |
| 2016-09-30 | $58.94B | $75.07B | 0.79 |
| 2016-06-30 | $58.90B | $72.53B | 0.81 |
| 2016-03-31 | $60.56B | $71.89B | 0.84 |
| 2015-12-31 | $54.43B | $77.12B | 0.71 |
| 2015-09-30 | $56.14B | $76.79B | 0.73 |
| 2015-06-30 | $56.58B | $78.83B | 0.72 |
| 2015-03-31 | $58.49B | $76.44B | 0.77 |
| 2014-12-31 | $54.54B | $70.84B | 0.77 |
| 2014-09-30 | $53.95B | $71.42B | 0.76 |
| 2014-06-30 | $55.25B | $70.52B | 0.78 |
| 2014-03-31 | $55.00B | $70.34B | 0.78 |
| 2013-12-31 | $51.78B | $74.47B | 0.70 |
| 2013-09-30 | $52.42B | $72.18B | 0.73 |
| 2013-06-30 | $51.44B | $69.63B | 0.74 |
| 2013-03-31 | $53.86B | $67.15B | 0.80 |
| 2012-12-31 | $54.93B | $69.26B | 0.79 |
| 2012-09-30 | $54.01B | $67.21B | 0.80 |
| 2012-06-30 | $54.25B | $64.24B | 0.84 |
| 2012-03-31 | $56.21B | $63.20B | 0.89 |
| 2011-12-31 | $51.56B | $65.94B | 0.78 |
| 2011-09-30 | $55.24B | $66.14B | 0.84 |
| 2011-06-30 | $58.82B | $67.09B | 0.88 |
| 2011-03-31 | $61.88B | $65.34B | 0.95 |
| 2010-12-31 | $53.55B | $69.77B | 0.77 |
| 2010-09-30 | $58.41B | $66.22B | 0.88 |
| 2010-06-30 | $41.11B | $55.82B | 0.74 |
| 2010-03-31 | $40.58B | $55.22B | 0.74 |
| 2009-12-31 | $38.04B | $57.46B | 0.66 |
| 2009-09-30 | $37.37B | $53.31B | 0.70 |
| 2009-06-30 | $33.79B | $50.49B | 0.67 |
| 2009-03-31 | $31.74B | $46.23B | 0.69 |
| 2008-12-31 | $27.86B | $50.44B | 0.55 |
| 2008-09-30 | $31.28B | $50.74B | 0.62 |
| 2008-06-30 | $31.79B | $51.61B | 0.62 |
| 2008-03-31 | $27.05B | $49.27B | 0.55 |
| 2007-12-31 | $26.06B | $49.40B | 0.53 |
| 2007-09-30 | $27.44B | $49.49B | 0.55 |
| 2007-06-30 | $26.96B | $43.66B | 0.62 |
| 2007-03-31 | $27.82B | $40.50B | 0.69 |
| 2006-12-31 | $26.71B | $41.29B | 0.65 |
| 2006-09-30 | $28.27B | $38.59B | 0.73 |
| 2006-06-30 | $28.77B | $37.16B | 0.77 |
| 2006-03-31 | $25.09B | $33.75B | 0.74 |
| 2005-12-31 | $24.57B | $33.16B | 0.74 |
| 2005-09-30 | $22.92B | $31.75B | 0.72 |
| 2005-06-30 | $22.64B | $30.40B | 0.75 |
| 2005-03-31 | $20.17B | $29.47B | 0.69 |
| 2004-12-31 | $21.17B | $31.32B | 0.68 |
| 2004-09-30 | $19.00B | $28.92B | 0.66 |
| 2004-06-30 | $18.94B | $28.30B | 0.67 |
| 2004-03-31 | $19.33B | $27.77B | 0.70 |
| 2003-12-31 | $18.80B | $30.52B | 0.62 |
| 2003-09-30 | $17.79B | $28.54B | 0.62 |
| 2003-06-30 | $19.16B | $26.48B | 0.72 |
| 2003-03-31 | $18.65B | $28.01B | 0.67 |
| 2002-12-31 | $16.69B | $28.34B | 0.59 |
| 2002-09-30 | $15.12B | $25.65B | 0.59 |
| 2002-06-30 | $15.06B | $27.79B | 0.54 |
| 2002-03-31 | $14.38B | $24.69B | 0.58 |
| 2001-12-31 | $14.61B | $25.15B | 0.58 |
| 2000-12-31 | $14.61B | $25.15B | 0.58 |
| 1999-12-31 | $19.21B | $25.61B | 0.75 |
| 1998-12-31 | $17.13B | $21.66B | 0.79 |
| 1997-12-31 | $17.22B | $18.44B | 0.93 |
| 1996-12-31 | $24.43B | $23.45B | 1.04 |
| 1995-12-31 | $21.30B | $21.44B | 0.99 |
| 1995-06-30 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $293.951B | $54.532B |
| Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |